Novartis to acquire The Medicines Company for USD 9.7 bn, adding inclisiran, a potentially transformational investigational cholesterol-lowering therapy to address leading global cause of death

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. SPCX
3. MU
4. ACN
5. IBM
6. SPY
7. TSLA
8. DPZ
9. NVDA
10. PRIM

Go back to Novartis to acquire The Medicines Company for USD 9.7 bn, adding inclisiran, a potentially transformational investigational cholesterol-lowering therapy to address leading global cause of death

SVB Leerink Downgrades The Medicines Company (MDCO) to Market Perform

November 25, 2019 8:10 PM EST

SVB Leerink analyst Joseph Schwartz downgraded The Medicines Company (NASDAQ: MDCO) from Outperform to Market Perform with a price target of $85.00 (from $78.00).

For an analyst ratings summary and ratings history on The Medicines Company... More